Bridge Bioresearch (BBR), based in London, has received approval for a phase IIa trial concerning diabetic foot ulcer treatment with isoniazide.

The target molecule has patent protection for treatment based on it being embedded into a wound dressing and/or as a traditional tablet. Preliminary evidence has shown that isoniazide reduces the healing time of difficult to heal wounds such as pressure ulcers, chronic/venous ulcers and diabetic ulcers.

Embedding the treatment directly into the dressing instead of applying it systematically could increase local therapeutic effect, reduce systemic side effects of the treatment and increase the ease of the use of the product. Currently no effective treatments exist for the chronic wounds.

The present invention indicates much faster healing time, possibly up to a 50% reduction in healing time, resulting in three months of therapy on average for the new product, equivalent to approximately 34 dressings being used for patients at 2.5 dressings per week.